Report ID: 10086100 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
"Transdermal drug delivery system market overview: The global transdermal drug delivery system market is estimated to be valued at ~USD 40 billion by the end of 2021 and is expected to mark a CAGR of ~10% over the period 2022-2030. Transdermal drug delivery systems are an alternative to intravascular, subcutaneous and transmucosal oral routes, where drugs are delivered through the skin for therapeutic use. It is expected that the increase in the elderly population and the increase in the number of patients with chronic diseases will promote the growth of the market. In addition, the increasing use of third-generation transdermal drug delivery systems, such as iontophoresis, is driving market growth. However, the shortcomings of these delivery systems, such as application site irritation and edema, are expected to hinder market growth.
INCREASING INCIDENCE OF CHRONIC DISEASES:
According to estimates by the World Health Organization, more than 422 million people worldwide were diagnosed with diabetes in 2014. The incidence of diabetes. For example, older people (> 65 years old) are more likely to develop type 2 diabetes. Growth in the Asia-Pacific region: Due to the large number of patients with chronic diseases, the Asia-Pacific region provides a lucrative opportunity for market growth. , Such as high blood pressure.
According to the CADI Research Foundation, hypertension is the most common disease in India. From this fact, it is obvious that the number of hypertensive patients is expected to increase from 118 million in 2000 to 214 million in 2025. Therefore, the high incidence of cardiovascular diseases (such as hypertension) makes it an attractive market for transdermal drug delivery systems. Expand the range of drugs expected to be administered transdermally. For example, new technologies, such as improved microneedle delivery, promote the delivery of drugs through the skin without causing pain.
The global market for transdermal drug delivery systems is segmented according to drug delivery system types, applications, and regions. According to the type of management system, it is divided into passive management systems and active management systems. Passive management system is divided into matrix systems and warehouse systems. Active transmission systems are divided into structure-based, power-based, and so on. According to the purpose, it is divided into pain relievers, hormone replacement therapy, cardiovascular disease, motion sickness, smoking cessation, etc. Analysis is conducted in North America, Europe, Asia Pacific and LAMEA. The main market companies include Novartis, Johnson & Johnson, Mylan, Boehringer Ingelheim, Bayer, and Bristol-Myers Squibb. , GlaxoSmithKline plc, Acrux Limited, Echo Therapeutics, Inc. and Endo Pharmaceuticals Inc.
MAIN ADVANTAGES :
The study provides an in-depth analysis of the global transdermal drug delivery system market, including current trends and future estimates, to clarify the upcoming investment pockets. It is expected that the quantitative analysis from 2022-2030 will enable stakeholders to take advantage of current market opportunities and provide an analysis of all geographic regions to identify major opportunities. Conduct comprehensive analysis by closely monitoring the positioning of key products and tracking major competitors within the market framework.
TRANSDERMAL DRUG DELIVERY KEY MARKET SEGMENTS:
By drug delivery system type Passive matrix system Reservoir system Active structure-based iontophoresis."
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10086100 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
